Copeptin in acute coronary syndromes and heart failure management: State of the art and future directions
| Autor: | Gilles Lemesle, Patrick Goldstein, Christophe Bauters, Nicolas Lamblin, Guillaume Schurtz |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Chest Pain
Hypothalamo-Hypophyseal System medicine.medical_specialty Time Factors Douleur thoracique Myocardial Infarction Nipecotic Acids Acute coronary syndromes Kidney Chest pain Coronary artery disease Risk Assessment Piperazines Copeptin Troponin T Predictive Value of Tests medicine Humans Multicenter Studies as Topic In patient Prospective Studies Acute Coronary Syndrome Disease management (health) Intensive care medicine Randomized Controlled Trials as Topic Copeptine Heart Failure Ejection fraction business.industry Glycopeptides Disease Management General Medicine Syndrome coronaire aigu Prognosis medicine.disease Insuffisance cardiaque Early Diagnosis Heart failure Coronaropathie medicine.symptom Cardiology and Cardiovascular Medicine business Biomarkers Mace Forecasting |
| Zdroj: | Archives of Cardiovascular Diseases. 108:398-407 |
| ISSN: | 1875-2136 |
| DOI: | 10.1016/j.acvd.2015.04.002 |
| Popis: | SummaryOver the past two decades, the use of multiple biomarkers has changed cardiovascular disease management. Recently, several trials have assessed the diagnostic and prognostic performances of copeptin, especially in patients with heart failure or acute coronary syndromes. Primary results are interesting, with copeptin looking promising for: the management of patients who present at emergency departments early after chest pain onset and the risk stratification of patients with heart failure. The purpose of this article is to review the data on the place of copeptin in the management of patients with chest pain or heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect